NCT07734883Not yet recruiting
Prevalence and Clinical Outcome of Eosinophilic COPD
Prevalence and Clinical Outcome of Eosinophilic COPD at Assiut University
Source: ClinicalTrials.gov · Last updated 29 Jul 2026
Brief summary (registry, in English)
Chronic Obstructive Pulmonary Disease (COPD) is a lung condition characterized by chronic breathing symptoms and progressive airflow blockages. A specific type of COPD, known as eosinophilic COPD, involves higher levels of white blood cells called eosinophils and is known to influence disease outcomes and treatment responses. Currently, there is limited data regarding the prevalence and clinical outcomes of eosinophilic COPD in Upper Egypt, particularly among patients at Assiut University Hospitals. The main objective of this prospective observational study is to determine how common eosinophilic COPD is among patients experiencing an acute worsening of their COPD symptoms (an exacerbation) at Assiut University Hospitals. The study also aims to evaluate the clinical outcomes associated with this specific phenotype. Researchers will observe patients over the age of 40 with a confirmed COPD diagnosis who are admitted to the hospital for an acute exacerbation. As part of their standard hospital care, participants will undergo routine clinical assessments, including a review of their medical history, physical examinations, lung function tests (spirometry), and standard blood tests to measure their blood eosinophil count. The study will compare patients with eosinophilic COPD to those with non-eosinophilic COPD. Researchers will specifically evaluate differences in the severity of the exacerbation, the duration of the hospital stay, and the need for ventilator support. The findings aim to contribute to better, more personalized treatment strategies and improved clinical outcomes for COPD patients in the region.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 70 (estimated)
- First submitted
- 25 Jul 2026
- Start date
- 1 Aug 2026
- Primary completion date
- 31 Aug 2027
- Lead sponsor
- Assiut University
- Diseases
- COPD
- NCT number
- NCT07734883
What you commit to
- Study type: Observational
- Planned participants: 70
- From 1 Aug 2026 to the primary completion date, 31 Aug 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving systemic corticosteroids within the previous 4 weeks.
Other illness
- Active pulmonary tuberculosis.
- Parasitic infections confirmed by stool analysis.
Lab values
- Hematological disorders affecting eosinophil count.
Other
- Patients with asthma or asthma-COPD overlap.
- Patients who need ICU admission.
Who the study is looking for
- Patients aged \> 40 years.
- Confirmed diagnosis of COPD according to GOLD 2026 guidelines.
- Presented with acute exacerbation of COPD (AECOPD) characterized by the onset or worsening of at least two symptoms (cough, phlegm, purulent sputum, wheezing, or dyspnea) persisting for a minimum of 48 hours, excluding other potential causes, such as left or right cardiac dysfunction, pulmonary embolism, pneumothorax, pleural effusion, arrhythmia and other related diseases.
Age in the registry: 40 years to - · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.